Cooley Closes 2nd Life Sciences Deal In 2 Days

Law360, New York (October 18, 2012, 4:50 PM EDT) -- Cooley LLP has closed its second sell-side pharmaceutical deal of the week, representing Presidio Pharmaceuticals Inc. in its $101 million acquisition by BioCryst Pharmaceutical Inc., announced Thursday.

That follows Tuesday's announcement that the California-based firm, whose mergers and acquisitions practice has a strong bent toward life sciences and technology, advised Surpass Medical Ltd. in its acquisition by Stryker Corp. for $135 million.

In Thursday's deal, BioCryst will issue 24.5 million shares, valued at $4.11 apiece at Wednesday's close, for privately held Presidio to team up on...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.